Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From uniQure N.V.
The gene therapy EtranaDez for hemophilia B placed on clinical hold after a patient was diagnosed with liver cancer, but UniQure points to that patient’s extensive history of liver disease.
UniQure has a potential first-mover advantage, but Freeline study's investigator compares FLT180a to later model smartphones with bugs fixed.
Unveiling its latest data, UniQure is tipped to avoid the knockback which affected BioMarin’s hemophilia A gene therapy, with a filing expected in the second half of 2021.
The company plans to file with 52-week data for AMT-061 and is confident it won't face the same stringent requirements from the FDA that led to a complete response letter for BioMarin's Roctavian.
- Drug Delivery
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Amsterdam Molecular Therapeutics (AMT)
- InoCard GmbH
- uniQure Germany GmbH
- uniQure U.S.A.
- uniQure The Netherlands
- uniQure Inc.